Please Wait...

PIIINP // Intact N-Terminal Propeptide Of Type III Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Type III collagen is present in many tissues, such as skin, vascular vessels, ligaments, skeletal muscles, synovial membrane and connective tissues. Type III collagen is an homotrimer of α1 chains encoded by a single gene (Wu et al., 2010). Collagen type III is synthetized as a large procollagen which is subjected to cleavage of its N-terminal peptide and this N-terminal propeptide of collagen type III (PIINP) is released in the blood circulation in direct proportion to newly formed type III collagen. Serum levels of PIIINP are elevated in remodeling tissues and in some diseases with fibrosis (Chalikias and Tziakas, 2015; Cohen, 2012).

Bioclinica Lab employs a manual competitive radioimmunoassay for the measurement of intact PIIINP in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)